A patient of multiple myeloma presents with bony lesions. What is the best marker for prognosis of the disease:
**Core Concept**
Multiple myeloma is a type of plasma cell dyscrasia characterized by the proliferation of malignant plasma cells in the bone marrow, leading to bone destruction and various systemic complications. The prognosis of multiple myeloma is influenced by various clinical and laboratory parameters, including the level of serum monoclonal protein (M-protein) and the presence of certain cytogenetic abnormalities.
**Why the Correct Answer is Right**
Beta2-microglobulin (β2-microglobulin) is a reliable marker for prognosis in multiple myeloma. Elevated levels of β2-microglobulin are associated with a higher tumor burden, increased renal impairment, and a poorer prognosis. The serum β2-microglobulin level is measured in mg/L and is used in combination with other prognostic factors, such as the International Staging System (ISS), to predict patient outcomes and guide treatment decisions.
**Why Each Wrong Option is Incorrect**
* **Option A:** Serum calcium levels are not a reliable marker for prognosis in multiple myeloma, although hypercalcemia can be a presenting feature of the disease.
* **Option B:** Serum albumin levels are not a direct marker for prognosis in multiple myeloma, although low serum albumin can be associated with advanced disease and poor nutritional status.
* **Option C:** Serum lactate dehydrogenase (LDH) levels can be elevated in multiple myeloma, particularly in patients with advanced disease, but are not as specific or reliable a marker for prognosis as β2-microglobulin.
**Clinical Pearl / High-Yield Fact**
The serum β2-microglobulin level is a critical prognostic factor in multiple myeloma, and its measurement should be included in the initial evaluation and follow-up of patients with this disease.
**Correct Answer: D. Beta2-microglobulin.**